For gene therapy, now-quantified risks are deemed troubling.
Twombly
Renee
R
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D002986:Clinical Trials as Topic; D004268:DNA-Binding Proteins / Q000235:genetics*; D032984:Ethics, Research; D005060:Europe; D005602:France; D015316:Genetic Therapy / Q000009:adverse effects* / Q000941:ethics / Q000379:methods; D005822:Genetic Vectors / Q000009:adverse effects*; D006801:Humans; D007231:Infant, Newborn; D007258:Informed Consent; D060588:LIM Domain Proteins; D009052:Leukemia Virus, Murine; D008297:Male; D008667:Metalloproteins / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012306:Risk; D016511:Severe Combined Immunodeficiency / Q000235:genetics* / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration; D014960:X Chromosome / Q000235:genetics*
D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D011518:Proto-Oncogene Proteins